Neogen (NEOG) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.08
- Estimate
- $0.05
- Surprise
- +50.0%
- Revenue (period 2026-08-31)
- $222.8M
- Score today
- 5.7/10
Revenue source: xbrl.
How the report landed
Neogen (NEOG) beat the $0.05 estimate with adjusted EPS of $0.08 — a large 50.0% upside surprise.
Coverage in the report window
- Why Is Neogen Stock Gaining Thursday? — benzinga, 2026-10-08
- Reported Earlier, Neogen Outlines Growth And Margin Expansion Strategy At 2026 Investor Day, Targeting High-Single-Digit — benzinga, 2026-10-08
- Neogen Shifts Focus to Scale Profitable Growth — benzinga, 2026-10-07
Where TrendMatrix's rating stands now
TrendMatrix currently rates NEOG Sell at 5.7/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +50.0% surprise compares with a +56.9% four-quarter average. Next scheduled report: 2027-01-07.
What argues against it
- Concentration risk — Supplier: sole or single source raw materials and products
- Target reached (-4.0% upside)
- Quality below floor (3.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.40
- Stop
- $11.53
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
NEOG at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $2.67B
- P/E (fwd)
- 27.1
- 52-week range
- $5.37–$14.26
- Off 52-week high
- 13.0%
- RSI (14)
- 64
- Volume vs avg
- 0.04×
- Score today
- 5.7/10